IntelliCap Oral Drug Delivery System Wins European Innovation Award
News Nov 20, 2014
The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.
As Medimetrics CEO Olaf Weiner explained: “We are delighted to win this award, in recognition of the unique capabilities of the technology behind our drug delivery systems. The use of IntelliCap will help deliver a revolution in healthcare which both saves costs and improves the outcomes for patients.”
The IntelliCap system was introduced into the market in 2011. An increasing number of pharma companies are using this powerful tool in the early-stage development and life cycle management of drugs. This unique, interactive device enables personalization of medications and treatments, empowering scientists to establish quickly the effective medication dose and delivery requirements. This reduces the risk of failure in expensive, late stage clinical trials, due to lack of safety or efficacy.
While the IntelliCap system is applied to speed the development of new products, the technology’s strength is its ability to enable the development of other pioneering products.
As Dr Weiner added: “The spirit of the award was to recognize the potential of the IntelliCap technology. Its ability to adapt and personalize during delivery will help usher in an era of smart pharmaceuticals to the benefit of patients.”
An early example is in the field of women’s health. LiGalli, a pioneering Dutch company led by Dr. Willem de Laat, is integrating the technology into a novel vaginal drug delivery system that enables new therapies.
In another example, IntelliCap technology creates a means of sampling and mapping content from the small intestine to identify its microbiological composition, in a non-invasive way. The mapping process will provide novel insights into how certain foods and also therapeutic agents might react in the gut and so affect our health.
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?READ MORE
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent painful swellings of the skin and mucous membranes. A new drug has been developed to help prevent attacks of hereditary angioedema. It has now been investigated in an international study performed at over 26 university facilities in Europe, Canada and Australia.READ MORE